Japan’s intracranial stents market rises amidst hospital backlogs | Health Care Asia Magazine

Japan’s intracranial stents market rises amidst hospital backlogs

The device is mainly used for patients with intracranial atherosclerotic disease (ICAD).

The intracranial stents market in Japan is expected to grow at a compound annual growth rate of about 14% between 2020 and 2025, as hospitals work through the backlog of neurological procedures amidst vaccinations, according to a report from GlobalData.

Although intracranial stenting procedure is rarely performed, it is driven in Japan by a rising prevalence of ICAD to which it is performed, as well as high awareness of stroke and ICAD, GlobalData’s medical devices analyst Anusha Kaushik said.

Previously, percutaneous transluminal angioplasty (PTA) was performed on ICAD patients in Japan with intracranial stenosis; and balloon-expandable coronary stents were sometimes used off-label to treat post-PTA restenosis.

However, the Japanese national health insurance system has now started reimbursement for intracranial stenting procedures which is expected to result in higher procedure volumes in the coming years.

“Intracranial stenting is expected to grow in Japan due to factors such as increased training and experience of healthcare professionals, increased usage of stents for rescue therapy in acute stroke patients, and the successful reporting of long-term stenting results,” Kaushik added.

Get Health Care Asia Magazine in your inbox
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

The majority of the country’s pharma manufacturing produces generic drugs.
This is expected to affect local pharma growth in the short term.
Nonetheless, more than half of the age group found its use to be comfortable.
The group’s profits after tax ballooned by as much as 138.4%.
Funds will be used to build out its behavioural health and chronic care modules.
Some players have been highly active in digital channels of various countries.
It has also formed a JV with Acurio to develop a private hospital in NSW.
With this, the company now offers an all-in-one patient management service.
The therapy can be done in eight different languages.
The country is expected to have one in five of its population to be elderly by 2050.
Sunway is planning to ramp up its hospital capacity to about 3,000 beds.
The system will help city managers to track epidemic conditions, real-time.
It is funded through the 2020 Primary Healthcare Research Data Infrastructure grants.
The hospital features 200 general inpatient beds and 100 hemodialysis beds.
The platform expanded its services after obtaining an internet hospital license.